Single-Dose Fluconazole Therapy for Oral Thrush in Hospice and Palliative Medicine Patients
Background: Oral thrush is a common fungal infection of the mouth experienced by palliative medicine and hospice patients who have advanced cancer. Individuals often experience distressing symptoms that affect their oral intake with most regimens adding to pill burden. This is an open-label prospect...
Gespeichert in:
| Veröffentlicht in: | American journal of hospice & palliative medicine 2017-08, Vol.34 (7), p.645-649 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 649 |
|---|---|
| container_issue | 7 |
| container_start_page | 645 |
| container_title | American journal of hospice & palliative medicine |
| container_volume | 34 |
| creator | Lagman, Ruth Davis, Mellar LeGrand, Susan Walsh, Declan Parala, Armida Gamier, Pamela Cothren, Brenda Cheema, Bushra Gopal, Sumi Rybicki, Lisa |
| description | Background:
Oral thrush is a common fungal infection of the mouth experienced by palliative medicine and hospice patients who have advanced cancer. Individuals often experience distressing symptoms that affect their oral intake with most regimens adding to pill burden. This is an open-label prospective observational study to assess the efficacy of a single-dose fluconazole 150 mg for oral thrush.
Methods:
Palliative medicine and hospice patients with a clinical diagnosis of oral thrush, a life expectancy of more than 1 week, and were able to swallow were enrolled. Signs and symptoms were evaluated on day 1 prior to administration of 150 mg of fluconazole and between days 3 to 5 after treatment.
Results:
Of 57 patients, 55 (96.5%) had more than 50% improvement in signs and symptoms. Both the number and severity of symptoms changed significantly posttreatment (P < .001). Side effects were few.
Conclusion:
Single-dose fluconazole 150 mg is an effective treatment of oral thrush for individuals with advanced cancer. |
| doi_str_mv | 10.1177/1049909116643927 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1826682089</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1049909116643927</sage_id><sourcerecordid>1826682089</sourcerecordid><originalsourceid>FETCH-LOGICAL-c337t-9c17df0f03046f8632bb5cc482d16a04b225765e95a255a1142a5f296cf5563e3</originalsourceid><addsrcrecordid>eNp1UEtLAzEQDqJYX3dPkqOX1Tw22c1R1FpBqWA9eVjS7Gybkm5qsivUX29KqwfBuczwvWA-hM4puaK0KK4pyZUiilIpc65YsYeOqOJlxgoq9tOd6GzDD9BxjAtCOMtzeogGiS_TkCP0_mrbmYPszkfAQ9cb3-ov7wBP5hD0ao0bH_A4aJeA0Mc5ti0e-biyBrBua_yinbO6s5-An6G2xraQsM5C28VTdNBoF-Fst0_Q2_B-cjvKnsYPj7c3T5nhvOgyZWhRN6QhnOSyKSVn06kwJi9ZTaUm-ZQxUUgBSmgmhKY0Z1o0TEnTCCE58BN0uc1dBf_RQ-yqpY0GnNMt-D5WtGRSloyUKknJVmqCjzFAU62CXeqwriipNpVWfytNlotdej9dQv1r-OkwCbKtIOoZVAvfhzZ9-3_gNyFlfOM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1826682089</pqid></control><display><type>article</type><title>Single-Dose Fluconazole Therapy for Oral Thrush in Hospice and Palliative Medicine Patients</title><source>Access via SAGE</source><source>MEDLINE</source><creator>Lagman, Ruth ; Davis, Mellar ; LeGrand, Susan ; Walsh, Declan ; Parala, Armida ; Gamier, Pamela ; Cothren, Brenda ; Cheema, Bushra ; Gopal, Sumi ; Rybicki, Lisa</creator><creatorcontrib>Lagman, Ruth ; Davis, Mellar ; LeGrand, Susan ; Walsh, Declan ; Parala, Armida ; Gamier, Pamela ; Cothren, Brenda ; Cheema, Bushra ; Gopal, Sumi ; Rybicki, Lisa</creatorcontrib><description>Background:
Oral thrush is a common fungal infection of the mouth experienced by palliative medicine and hospice patients who have advanced cancer. Individuals often experience distressing symptoms that affect their oral intake with most regimens adding to pill burden. This is an open-label prospective observational study to assess the efficacy of a single-dose fluconazole 150 mg for oral thrush.
Methods:
Palliative medicine and hospice patients with a clinical diagnosis of oral thrush, a life expectancy of more than 1 week, and were able to swallow were enrolled. Signs and symptoms were evaluated on day 1 prior to administration of 150 mg of fluconazole and between days 3 to 5 after treatment.
Results:
Of 57 patients, 55 (96.5%) had more than 50% improvement in signs and symptoms. Both the number and severity of symptoms changed significantly posttreatment (P < .001). Side effects were few.
Conclusion:
Single-dose fluconazole 150 mg is an effective treatment of oral thrush for individuals with advanced cancer.</description><identifier>ISSN: 1049-9091</identifier><identifier>EISSN: 1938-2715</identifier><identifier>DOI: 10.1177/1049909116643927</identifier><identifier>PMID: 27188880</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antifungal Agents - administration & dosage ; Antifungal Agents - therapeutic use ; Candidiasis, Oral - drug therapy ; Female ; Fluconazole - administration & dosage ; Fluconazole - therapeutic use ; Hospice Care - methods ; Humans ; Male ; Middle Aged ; Neoplasms - complications ; Neoplasms - therapy ; Nursing ; Palliative Care - methods ; Prospective Studies</subject><ispartof>American journal of hospice & palliative medicine, 2017-08, Vol.34 (7), p.645-649</ispartof><rights>The Author(s) 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c337t-9c17df0f03046f8632bb5cc482d16a04b225765e95a255a1142a5f296cf5563e3</citedby><cites>FETCH-LOGICAL-c337t-9c17df0f03046f8632bb5cc482d16a04b225765e95a255a1142a5f296cf5563e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/1049909116643927$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/1049909116643927$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21819,27924,27925,43621,43622</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27188880$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lagman, Ruth</creatorcontrib><creatorcontrib>Davis, Mellar</creatorcontrib><creatorcontrib>LeGrand, Susan</creatorcontrib><creatorcontrib>Walsh, Declan</creatorcontrib><creatorcontrib>Parala, Armida</creatorcontrib><creatorcontrib>Gamier, Pamela</creatorcontrib><creatorcontrib>Cothren, Brenda</creatorcontrib><creatorcontrib>Cheema, Bushra</creatorcontrib><creatorcontrib>Gopal, Sumi</creatorcontrib><creatorcontrib>Rybicki, Lisa</creatorcontrib><title>Single-Dose Fluconazole Therapy for Oral Thrush in Hospice and Palliative Medicine Patients</title><title>American journal of hospice & palliative medicine</title><addtitle>Am J Hosp Palliat Care</addtitle><description>Background:
Oral thrush is a common fungal infection of the mouth experienced by palliative medicine and hospice patients who have advanced cancer. Individuals often experience distressing symptoms that affect their oral intake with most regimens adding to pill burden. This is an open-label prospective observational study to assess the efficacy of a single-dose fluconazole 150 mg for oral thrush.
Methods:
Palliative medicine and hospice patients with a clinical diagnosis of oral thrush, a life expectancy of more than 1 week, and were able to swallow were enrolled. Signs and symptoms were evaluated on day 1 prior to administration of 150 mg of fluconazole and between days 3 to 5 after treatment.
Results:
Of 57 patients, 55 (96.5%) had more than 50% improvement in signs and symptoms. Both the number and severity of symptoms changed significantly posttreatment (P < .001). Side effects were few.
Conclusion:
Single-dose fluconazole 150 mg is an effective treatment of oral thrush for individuals with advanced cancer.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antifungal Agents - administration & dosage</subject><subject>Antifungal Agents - therapeutic use</subject><subject>Candidiasis, Oral - drug therapy</subject><subject>Female</subject><subject>Fluconazole - administration & dosage</subject><subject>Fluconazole - therapeutic use</subject><subject>Hospice Care - methods</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasms - complications</subject><subject>Neoplasms - therapy</subject><subject>Nursing</subject><subject>Palliative Care - methods</subject><subject>Prospective Studies</subject><issn>1049-9091</issn><issn>1938-2715</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1UEtLAzEQDqJYX3dPkqOX1Tw22c1R1FpBqWA9eVjS7Gybkm5qsivUX29KqwfBuczwvWA-hM4puaK0KK4pyZUiilIpc65YsYeOqOJlxgoq9tOd6GzDD9BxjAtCOMtzeogGiS_TkCP0_mrbmYPszkfAQ9cb3-ov7wBP5hD0ao0bH_A4aJeA0Mc5ti0e-biyBrBua_yinbO6s5-An6G2xraQsM5C28VTdNBoF-Fst0_Q2_B-cjvKnsYPj7c3T5nhvOgyZWhRN6QhnOSyKSVn06kwJi9ZTaUm-ZQxUUgBSmgmhKY0Z1o0TEnTCCE58BN0uc1dBf_RQ-yqpY0GnNMt-D5WtGRSloyUKknJVmqCjzFAU62CXeqwriipNpVWfytNlotdej9dQv1r-OkwCbKtIOoZVAvfhzZ9-3_gNyFlfOM</recordid><startdate>201708</startdate><enddate>201708</enddate><creator>Lagman, Ruth</creator><creator>Davis, Mellar</creator><creator>LeGrand, Susan</creator><creator>Walsh, Declan</creator><creator>Parala, Armida</creator><creator>Gamier, Pamela</creator><creator>Cothren, Brenda</creator><creator>Cheema, Bushra</creator><creator>Gopal, Sumi</creator><creator>Rybicki, Lisa</creator><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201708</creationdate><title>Single-Dose Fluconazole Therapy for Oral Thrush in Hospice and Palliative Medicine Patients</title><author>Lagman, Ruth ; Davis, Mellar ; LeGrand, Susan ; Walsh, Declan ; Parala, Armida ; Gamier, Pamela ; Cothren, Brenda ; Cheema, Bushra ; Gopal, Sumi ; Rybicki, Lisa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c337t-9c17df0f03046f8632bb5cc482d16a04b225765e95a255a1142a5f296cf5563e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antifungal Agents - administration & dosage</topic><topic>Antifungal Agents - therapeutic use</topic><topic>Candidiasis, Oral - drug therapy</topic><topic>Female</topic><topic>Fluconazole - administration & dosage</topic><topic>Fluconazole - therapeutic use</topic><topic>Hospice Care - methods</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasms - complications</topic><topic>Neoplasms - therapy</topic><topic>Nursing</topic><topic>Palliative Care - methods</topic><topic>Prospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lagman, Ruth</creatorcontrib><creatorcontrib>Davis, Mellar</creatorcontrib><creatorcontrib>LeGrand, Susan</creatorcontrib><creatorcontrib>Walsh, Declan</creatorcontrib><creatorcontrib>Parala, Armida</creatorcontrib><creatorcontrib>Gamier, Pamela</creatorcontrib><creatorcontrib>Cothren, Brenda</creatorcontrib><creatorcontrib>Cheema, Bushra</creatorcontrib><creatorcontrib>Gopal, Sumi</creatorcontrib><creatorcontrib>Rybicki, Lisa</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of hospice & palliative medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lagman, Ruth</au><au>Davis, Mellar</au><au>LeGrand, Susan</au><au>Walsh, Declan</au><au>Parala, Armida</au><au>Gamier, Pamela</au><au>Cothren, Brenda</au><au>Cheema, Bushra</au><au>Gopal, Sumi</au><au>Rybicki, Lisa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Single-Dose Fluconazole Therapy for Oral Thrush in Hospice and Palliative Medicine Patients</atitle><jtitle>American journal of hospice & palliative medicine</jtitle><addtitle>Am J Hosp Palliat Care</addtitle><date>2017-08</date><risdate>2017</risdate><volume>34</volume><issue>7</issue><spage>645</spage><epage>649</epage><pages>645-649</pages><issn>1049-9091</issn><eissn>1938-2715</eissn><abstract>Background:
Oral thrush is a common fungal infection of the mouth experienced by palliative medicine and hospice patients who have advanced cancer. Individuals often experience distressing symptoms that affect their oral intake with most regimens adding to pill burden. This is an open-label prospective observational study to assess the efficacy of a single-dose fluconazole 150 mg for oral thrush.
Methods:
Palliative medicine and hospice patients with a clinical diagnosis of oral thrush, a life expectancy of more than 1 week, and were able to swallow were enrolled. Signs and symptoms were evaluated on day 1 prior to administration of 150 mg of fluconazole and between days 3 to 5 after treatment.
Results:
Of 57 patients, 55 (96.5%) had more than 50% improvement in signs and symptoms. Both the number and severity of symptoms changed significantly posttreatment (P < .001). Side effects were few.
Conclusion:
Single-dose fluconazole 150 mg is an effective treatment of oral thrush for individuals with advanced cancer.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>27188880</pmid><doi>10.1177/1049909116643927</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1049-9091 |
| ispartof | American journal of hospice & palliative medicine, 2017-08, Vol.34 (7), p.645-649 |
| issn | 1049-9091 1938-2715 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1826682089 |
| source | Access via SAGE; MEDLINE |
| subjects | Adult Aged Aged, 80 and over Antifungal Agents - administration & dosage Antifungal Agents - therapeutic use Candidiasis, Oral - drug therapy Female Fluconazole - administration & dosage Fluconazole - therapeutic use Hospice Care - methods Humans Male Middle Aged Neoplasms - complications Neoplasms - therapy Nursing Palliative Care - methods Prospective Studies |
| title | Single-Dose Fluconazole Therapy for Oral Thrush in Hospice and Palliative Medicine Patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T10%3A43%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Single-Dose%20Fluconazole%20Therapy%20for%20Oral%20Thrush%20in%20Hospice%20and%20Palliative%20Medicine%20Patients&rft.jtitle=American%20journal%20of%20hospice%20&%20palliative%20medicine&rft.au=Lagman,%20Ruth&rft.date=2017-08&rft.volume=34&rft.issue=7&rft.spage=645&rft.epage=649&rft.pages=645-649&rft.issn=1049-9091&rft.eissn=1938-2715&rft_id=info:doi/10.1177/1049909116643927&rft_dat=%3Cproquest_cross%3E1826682089%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1826682089&rft_id=info:pmid/27188880&rft_sage_id=10.1177_1049909116643927&rfr_iscdi=true |